News from pharmalink ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Aug 24, 2017, 04:00 ETThomas Eklund New Chairman of Pharmalink

The Swedish specialty pharmaceutical company Pharmalink AB today announced the appointment of Thomas Eklund as new Chairman of the board. Thomas...


Jun 04, 2017, 09:40 ETPositive Phase 2b Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Presented at Leading Kidney Disease Conference

Pharmalink AB, a specialty pharma company, is pleased to announce that its recent publication in The Lancet on the positive Phase 2b trial of...


May 31, 2017, 03:41 ETPositive Phase 2b Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

Pharmalink AB, a specialty pharma company, is pleased to announce that its recent publication in The Lancet on the positive Phase 2b trial of...


May 18, 2017, 02:00 ETPharmalink AB Announces the Appointment of a New Chief Executive Officer

Pharmalink AB, a specialty pharmaceutical company, announces the appointment of Renee Aguiar-Lucander as Chief Executive Officer. Pharmalink has...


Mar 29, 2017, 04:00 ETPositive Results of Phase 2b Clinical Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Published in The Lancet

Pharmalink AB, a specialty pharma company, announces that positive results and analyses from the completed Phase 2b trial of its oral drug candidate...


Jan 09, 2017, 02:00 ETPharmalink Strengthens Board with Appointment of Maria Carell as Chair

Pharmalink AB, a specialty pharma company, announces the election of Maria Carell as Chair of the company's Board of Directors*. Ms. Carell replaces...


Nov 29, 2016, 04:00 ETPharmalink Announces European Orphan Drug Designation For Nefecon® For Treatment Of Iga Nephropathy, An Inflammatory Kidney Disease

Pharmalink AB, a specialty pharma company, announces that the European Commission (EC) has granted Orphan Medicinal Product (OMP) designation in the...


Oct 01, 2015, 03:00 ETPharmalink Raises SEK100m to Advance Nefecon® Development as New Treatment for Kidney Disease

Plans Initial Public Offering on Nasdaq Stockholm in 2016 Pharmalink AB, a specialty pharma company, today announces it has raised SEK100 million...


Apr 14, 2015, 03:00 ETPharmalink Announces Positive Result in Phase 2b Trial of Nefecon®

IgA Nephropathy Primary Endpoint Met at a Planned Interim Analysis NEFIGAN Trial Hits Efficacy Target Based on Highly Statistically Significant...


Jan 21, 2015, 03:00 ETPharmalink Announces an Open Investigational New Drug (IND) Application for Nefecon®

Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces that its IND for Nefecon® is now open with the US Food &...


Nov 03, 2014, 03:00 ETData from Clinical Study of Pharmalink's Nefecon® to be Presented at American Society of Nephrology's Kidney Week 2014

Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces that clinical results from the initial run-in phase of its...


Oct 27, 2014, 04:00 ETPharmalink Extends Patent Protection for Nefecon® Treatment for Renal Disease

Key patent granted in Japan Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had an important patent for its...


Oct 14, 2014, 03:00 ETPharmalink Elects Bengt Julander as Chairman

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has elected Bengt Julander as Chairman of the Board of Directors. He...


Jul 10, 2014, 03:00 ETPharmalink's Core Patents for Nefecon® Treatment for Renal Disease Granted in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon®...


Jan 13, 2014, 03:00 ETPharmalink Completes Enrolment of Patients into Phase IIB Clinical Study (Nefigan) of Nefecon®

Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces it has completed recruitment of patients into a Phase IIb...


Dec 18, 2012, 04:37 ETPharmalink Initiates a Pivotal Phase IIb Trial with Nefecon® in Patients with Primary IgA Nephropathy

Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon® (Nefigan) in patients with...


Oct 29, 2012, 05:00 ETPharmalink AB Strengthens Senior Management Team

Dr. Heather Cook Appointed Director of Regulatory Affairs and Marek Poszepczynski as Director of Business Development Pharmalink AB, a Swedish...


Dec 13, 2011, 04:00 ETPharmalink AB Gains Exclusive Licence to Archimedes Pharma's TARGIT® Technology for Nefecon® (PL-56) Program

Pharmalink AB, today announces it has gained an exclusive global license to Archimedes Pharma Ltd.'s TARGIT® drug delivery technology for use in its...


Oct 13, 2010, 04:00 ETPharmalink AB Receives US Orphan Drug Designation for Nefecon(R) (PL-56)

Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA) for ...


Jun 30, 2010, 04:51 ETPharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome

- Agreement Marks Milestone in Pharmalink's Corporate Development Pharmalink AB, today announced that it has closed its agreement with Grifols SA for ...